CCL2 and neoplasm: In CHLA-255-Fluc mice, combination therapy with anti-CCL2 antibody and etoposide led to a significant decrease in tumor burden compared to the PBS control group (p = 0.02) and the anti-CCL2 antibody alone group (p = 0.05), but not compared to the etoposide alone group (Fig. 6A,B).